Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.
High-dose methotrexate with leucovorin rescue plus cyclophosphamide resulted in a 66.6% objective response rate with a 50% complete response rate. These preliminary results are higher than our previous results with melphalan alone or actinomycin D, 5-fluorouracil, and cyclophosphamide in women with advanced ovarian adenocarcinoma. Circulating ovarian cystadenocarcinoma-associated antigen serum levels were positive in 69.8% of patients and correlated with response to chemotherapy in 70% of patients. To date, all of the patients with advanced ovarian adenocarcinoma were found to have elevated galactosyltransferase levels. Galactosyltransferase levels correlated with response to therapy in the first five patients followed serially.
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy*; D000951:Antigens, Neoplasm / Q000032:analysis; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005700:Galactosyltransferases / Q000097:blood; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage*; D008727:Methotrexate / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D005700:Galactosyltransferases; D002955:Leucovorin; D008727:Methotrexate